Immunic Inc has completed a public share offering which is expected to raise $65 million from investors to advance its pipeline of small molecule therapies for chronic inflammatory and autoimmune diseases. The offering consists of pre-funded warrants to purchase stock in the company which can be exercised at different periods up until the end of the year. The offering was expected to close on or about 3 June.
Orionis Biosciences has announced a second strategic collaboration with Genentech to discover and develop a new class of monovalent molecular glue medicines for cancer, in a deal worth $105 million upfront and more than $2 billion in potential milestone payments.
France-based Sanofi SA posted strong sales and business operating income for the 2025 first quarter due to continued demand for Dupixent and a strong performance by newer treatments and vaccines. Sales reached €9.9 billion, up by 10.8% in actual exchange rates and by 9.7% at constant rates. Business operating income for the quarter was €2.9 billion, a rise of 20.1% on the first quarter of 2024. The company left its full-year profit and sales forecasts unchanged, with the expectation that sales will continue to grow strongly.
Research Strategy
The therapeutic potential of virus-like particles
By John Foerster
Cell and Gene Therapy
Engineering immune cell therapies;
will in vivo approaches work?
By Tim Farries
Interview
Lundbeck to test AI for treating brain disorders
Regulation and Policy
Pharmacovigilance at a crossroads
By Ravi Patel and Anna Melin
Science and Policy
First successful in vivo base editing
By Rosie Bannister
Lundbeck to test AI for treating brain disorders
(109.96 KB)
